Related Experiment Video
Updated: Jun 23, 2026

Ultrasonic Assessment of Myocardial Microstructure
Published on: January 14, 2014
Myocardial beta adrenoceptor density in primary and secondary left ventricular hypertrophy
L Choudhury1, S D Rosen, D C Lefroy
1MRC Clinical Sciences Centre, Hammersmith Hospital, London, U.K.
Insights
Myocardial beta-adrenoceptor density is reduced in both hypertrophic cardiomyopathy and secondary left ventricular hypertrophy. This down-regulation occurs even when the heart
Area of Science:
- Cardiology
- Molecular Cardiology
- Nuclear Cardiology
Background:
- Myocardial beta-adrenoceptor density is reduced in hypertrophic cardiomyopathy (HCM) with preserved systolic function.
- The presence of this down-regulation in secondary myocardial hypertrophy is not well-established.
Purpose of the Study:
- To determine if beta-adrenoceptor down-regulation is unique to HCM or also occurs in secondary myocardial hypertrophy.
- To compare beta-adrenoceptor density in patients with HCM, secondary left ventricular hypertrophy (LVH), and normal controls.
Main Methods:
- Positron emission tomography (PET) with 11C-CGP-12177 was used to measure myocardial beta-adrenoceptor density.
- Participants included 11 patients with HCM, 8 with secondary LVH (due to hypertension or aortic valve disease), and 18 controls.
- Control groups were age-matched to patient groups to account for age-related changes in beta-adrenoceptor density.
Main Results:
- Myocardial beta-adrenoceptor density was significantly lower in HCM patients (7.70 pmol/g) compared to matched controls (10.17 pmol/g).
- Myocardial beta-adrenoceptor density was also significantly lower in secondary LVH patients (6.35 pmol/g) compared to matched controls (9.16 pmol/g).
- Plasma catecholamine levels (noradrenaline and adrenaline) did not correlate with beta-adrenoceptor density in either patient group.
Conclusions:
- Myocardial beta-adrenoceptor density is comparably decreased in both primary (HCM) and secondary left ventricular hypertrophy.
- This down-regulation occurs despite preserved left ventricular systolic function in both conditions.
- The findings suggest a common mechanism of beta-adrenoceptor alteration in different forms of left ventricular hypertrophy.
Objectives:
Myocardial beta-adrenoceptor density has been found to be reduced in hypertrophic cardiomyopathy, even when systolic function is preserved. Our purpose in the current study was to investigate whether beta-adrenoceptor down-regulation was unique to hypertrophic cardiomyopathy, or is also present in secondary myocardial hypertrophy.
Methods:
Myocardial beta-adrenoceptor density was measured in 11 patients with hypertrophic cardiomyopathy, eight patients with left ventricular hypertrophy secondary to arterial hypertension or aortic valve disease and 18 normal control subjects, using positron emission tomography with 11C-CGP-12177 as the myocardial beta-adrenoceptor ligand.
Results:
Reflecting the natural incidence of the conditions, the age of the hypertrophic cardiomyopathy patients was 37 (10) [mean (SD), range 20-51] years and that of the secondary hypertrophy patients 64 (18), [range 26-80] years; P < 0.01. The controls' ages were 50 (13), [range 21-65] years; however, since beta-adrenoceptor density is known to be influenced by age, the controls' data was split into groups matched to the hypertrophic cardiomyopathy and secondary hypertrophy patient sets. For the hypertrophic cardiomyopathy patients, mean left ventricular beta-adrenoceptor was 7.70 (1.86) pmol.g-1 compared to 10.17 (2.44) pmol.g-1 for a matched set of 15 controls; P < 0.01. In secondary left ventricular hypertrophy, beta-adrenoceptor was 6.35 (1.70) pmol.g-1 compared to 9.16 (2.00) pmol.g-1 for a matched set of 10 controls; P < 0.01. Plasma noradrenaline was 5.5 (2.2) nmol.l-1 in hypertrophic cardiomyopathy and 2.5 (1.0) nmol.l-1 for the matched controls; P < 0.01. The results for adrenaline were 2.2 (1.1) vs 0.4 (0.3) nmol.l-1 respectively; P < 0.001. For the secondary hypertrophy patients, the corresponding figures were 2.5 (1.2) vs 2.5 (1.0) nmol.l-1 for noradrenaline for patients and controls respectively (P = ns); and for adrenaline 0.2 (0.1) and 0.3 (0.2) nmol.l-1 respectively, P = ns. On multiple regression analysis, no relationships could be demonstrated amongst plasma catecholamines, beta-adrenoceptor, myocardial blood flow and echocardiographic E/A ratio and fractional shortening.
Conclusion:
Myocardial beta-adrenoceptor density appears to be comparably decreased in both primary and secondary left ventricular hypertrophy in the presence of preserved left ventricular systolic function.
Related Concept Videos
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Action of β1 Blockers
Heart Failure Drugs: β-Blockers
Heart Failure II: Pathophysiology
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy

